

Cc: [redacted] [redacted]@rivm.nl; [redacted] [redacted]@rivm.nl; [redacted]

To: [redacted] [redacted]@hotmail.com; [redacted] [redacted]@hotmail.com; [redacted] [redacted]@ggdzeeland.nl; [redacted] [redacted]@gmail.com; [redacted] [redacted]@gmail.com; arts infectieziektebestrijding Bonaire [redacted] [redacted]@bonairegov.com; [redacted] [redacted]@bonairegov.com; [redacted] [redacted]@hoharuba.com; [redacted] [redacted]@gmail.com; [redacted] [redacted]@outlook.com; [redacted] [redacted]@rivm.nl; [redacted] [redacted]@sintmaartengov.org; [redacted] [redacted]@sintmaartengov.org; [redacted] [redacted]@hotmail.com; [redacted] [redacted] - MOH Sint Maarten ([redacted] [redacted]@sintmaartengov.org) [redacted] [redacted]@sintmaartengov.org; [redacted] [redacted]@despa.gov.aw; [redacted] [redacted]@statiagov.com; [redacted] [redacted]@statiagov.com; [redacted] [redacted]@ggdzeeland.nl; [redacted] [redacted]@gobiernu.cw; [redacted] [redacted]@gobiernu.cw; [redacted] [redacted]@gmail.com; [redacted] [redacted]@gmail.com; [redacted] [redacted]@gmail.com; [redacted] [redacted]@bonairegov.com; [redacted] [redacted]@bonairegov.com; [redacted] [redacted]@gmail.com; [redacted] [redacted]@sabagov.nl; [redacted] [redacted]@sabagov.nl; [redacted] [redacted]@gmail.com; [redacted] [redacted]@gmail.com; [redacted] [redacted]@xs4all.nl; [redacted] [redacted]@sintmaartengov.org; [redacted] [redacted]@bonairegov.com; [redacted] [redacted]@hotmail.com; [redacted] [redacted]@gobiernu.cw; [redacted] [redacted] - KLM; [redacted] [redacted]@klm.com; [redacted] [redacted]@hotmail.com; [redacted] [redacted]@hotmail.com; [redacted] [redacted]@statiagov.com; [redacted] [redacted]@statiagov.com; [redacted] [redacted]@gmail.com; [redacted] [redacted]@sintmaartengov.org; [redacted] [redacted]@sintmaartengov.org; [redacted] [redacted]@despa.gov.aw; [redacted] [redacted]@despa.gov.aw; [redacted] [redacted]@gmail.com; [redacted] [redacted]@gmail.com; [redacted] [redacted]@rivm.nl; [redacted] [redacted]@sintmaartengov.org; [redacted] [redacted]@sintmaartengov.org; [redacted] [redacted]@gobiernu.cw

From: [redacted]

Sent: Fri 1/29/2021 5:30:02 PM

Subject: Over vaccinatie efficacy


Received: Fri 1/29/2021 5:30:02 PM

Uit het ECDC Round table report:

COVID-19 associated with SARS-CoV-2 multi-country (world) 2019-2021
COVID-19 vaccine:

Novavax vaccine: a pivotal trial in the UK, including more than half of those cases infected with the B.1.1.7 variant, has resulted in a 89.3% efficacy of the Novavax vaccine. In total, the phase 3 trial included more than 15 000 study participants aged 18-84 years. In the South African part of the trial, where most of the cases were infected with the B.1.351 variant first identified in South Africa, the vaccine was seen observed to provide 60% efficacy among those without HIV.

According to German media, the National Immunisation Technical Advisory Group (STIKO) of the Robert Koch Institute recommends that the AstraZeneca COVID-19 vaccine should only be offered to people who are 18 to 64 years old. STIKO justified its assessment by stating that currently insufficient data were available to assess the efficacy of vaccinations in individuals aged 65 years and above.



Met vriendelijke groet,

[redacted]



[redacted] | Arts M&G, Infectieziektebestrijding
[redacted]

Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Landelijke Coördinatie Infectieziektebestrijding (LCI)
Antonie van Leeuwenhoeklaan 9 | 3721 MA | Bilthoven
Postbus 1 | 3720 BA | Bilthoven

030 5.1.2e | Mob. +31 5.1.2e | Kamer 5.1.2e
5.1.2e | @rvm.nl | www.rvm.nl